are increasingly recognized as key participants in various autoimmune diseases, including multiple sclerosis. Although sets of transcription factors and cytokines are known to regulate T H -17 differentiation, the role of noncoding RNA is poorly understood. Here we identify a T H -17 cell-associated microRNA, miR-326, whose expression was highly correlated with disease severity in patients with multiple sclerosis and mice with experimental autoimmune encephalomyelitis (EAE). In vivo silencing of miR-326 resulted in fewer T H -17 cells and mild EAE, and its overexpression led to more T H -17 cells and severe EAE. We also found that miR-326 promoted T H -17 differentiation by targeting Ets-1, a negative regulator of T H -17 differentiation. Our data show a critical role for microRNA in T H -17 differentiation and the pathogenesis of multiple sclerosis.
A r t i c l e s
After antigen stimulation, naive CD4 + helper T cells differentiate into effector T cells to participate in the adaptive immune response. Interleukin 17 (IL-17)-producing T helper cells (T H -17 cells) have been identified as a distinct subset of effector helper T cells that are essential in clearing foreign pathogens and inducing tissue inflammation during autoimmune disease 1, 2 . T H -17 differentiation is directed by lineage-specific transcription factors, including RORγt and RORα 3 , and is controlled by the coordinated activity of a series of positive and negative regulators [4] [5] [6] [7] . Although the list of molecular regulators of T H -17 differentiation is ever growing, possible factors that link the generation of T H -17 cells to pathological conditions, such as autoimmunity, are largely unknown and need to be clarified.
As a prototype of organ-specific autoimmune disease, multiple sclerosis is manifested by chronic inflammatory demyelination of the central nervous system (CNS) and is one of the foremost causes of nontraumatic neurological disability in young adults 8, 9 . The disease is clinically heterogeneous, with about 80% of patients developing the relapsing-remitting multiple sclerosis (RRMS) subtype 10 . Because of limited understanding of the pathogenesis of multiple sclerosis and a lack of sensitive biomarkers, according to the present criteria 11 , the diagnosis of multiple sclerosis still depends on repeated occurrence of the disease. In addition, the signs and symptoms of multiple sclerosis usually share considerable similarity with those of other CNS inflammatory diseases, such as neuromyelitis optica (NMO); this leads to considerable therapeutic and diagnostic difficulties. CD4 + T cell-mediated autoimmunity has long been accepted as one of the most important aspects of multiple sclerosis pathogenesis, especially for the early initiation of disease 12, 13 . T helper type 1 (T H 1) cells, characterized by the production of interferon-γ (IFN-γ), have been considered the type of effector helper T cells that mediate the pathogenesis of multiple sclerosis; subsequent studies have indicated that T H -17 cells are involved and are at least as critical as T H 1 cells in this pathogenesis. Mice with fewer T H -17 cells are less susceptible to experimental autoimmune encephalomyelitis (EAE) 14, 15 , and IL-17-expressing T cells have been found in lesions of brain tissues from patients with multiple sclerosis 16 . Despite the lines of evidence described above, the underlying mechanisms of T H -17 differentiation, as well as potential clinical applications, including the identification of T H -17-related diagnosis markers or the development of T H -17-targeting therapeutic approaches for multiple sclerosis, have not been established.
MicroRNAs represent a large family of endogenous noncoding RNAs that comprise a fundamental layer of post-transcriptional regulation of gene expression 17 . When poorly regulated, microRNAs are critically involved in a range of human diseases 18, 19 and potentially serve as good diagnostic markers 20 , prognostic markers 21 or therapeutic targets 19 . MicroRNAs also participate in the regulation of autoimmunity: deficiency in Dicer or Drosha leads to autoimmune signs in mice 22, 23 . However, which microRNAs are involved in the regulation and control of autoimmune disease is unclear.
Here we report that the microRNA miR-326 is critical in regulating T H -17 differentiation and hence contributes to the pathogenesis of multiple sclerosis. We found that miR-326 mediated T H -17 differentiation through translational inhibition of Ets-1 (A000889), a negative regulator of T H -17 differentiation. Knockdown or overexpression of miR-326 alleviated or aggravated EAE, respectively. In human patients with multiple sclerosis, miR-326 expression was upregulated, and this correlated with disease severity and IL-17 production. Collectively our results suggest that miR-326 is a T H -17 cell-associated microRNA that functions in the pathogenesis of multiple sclerosis.
RESULTS

Upregulation of miR-326 in patients with multiple sclerosis
By using clinical samples (Table 1) , we found that miR-326 expression was significantly higher in peripheral blood leukocytes (PBLs) of patients with RRMS (Fig. 1a) than in those of age-matched controls or patients with NMO, an inflammatory demyelinating CNS disease with symptoms that considerably overlap those of multiple sclerosis but an etiology distinct from that of multiple sclerosis 24 . Detailed analysis showed that PBLs from patients with relapsing multiple sclerosis had significantly higher miR-326 expression but those from patients with remitting multiple sclerosis did not (Fig. 1b) . In contrast, the expression of seven known immunologically relevant microRNAs showed no substantial changes (Supplementary Fig. 1 ), which suggested a specific association of miR-326 expression with relapsing multiple sclerosis. More notably, there was even more prominently enhanced miR-326 expression in the CD4 + T cell population but not in the CD8 + T cell or non-T cell populations of patients with multiple sclerosis (Fig. 1c) .
CD4 + T cells that participate in multiple sclerosis pathogenesis take on the phenotype of T H 1 cells, T H 2 cells, T H -17 cells or regulatory Drug treatment ---Relevant information about human subjects recruited for this study. Sample size is total number of subjects; age is presented in years ± s.e.m.; sex is total number (with percent of group in parentheses); '-' indicates 'not applicable'. Fig. 1c and Supplementary Fig. 2 ). We further confirmed the upregulation of Il17a in patients with relapsing multiple sclerosis at the protein level by intracellular cytokine staining of CD4 + T cells (Supplementary Fig. 3 ). Linear correlation analysis of transcripts of miR-326 and those cytokines in CD4 + T cells for patients with RRMS further demonstrated that only Il17a expression correlated well with that of miR-326 (Fig. 1d) . Consistent with that, by fluorescence in situ hybridization (FISH), we found coexpression of miR-326 and Il17a in CD4 + T cells of patients with relapsing multiple sclerosis (Fig. 1e,f) , which showed that miR-326 was expressed in the T H -17 cell population. This was further confirmed by the high expression of miR-326 in CCR6 + CD4 + PBLs of patients with relapsing multiple sclerosis (Fig. 1g) , a population that identifies most human T H -17 cells 25 . These results demonstrate that T H -17 cells have high expression of miR-326 and that miR-326 expression significantly correlates with multiple sclerosis severity.
Regulation of EAE development by miR-326
Expression of miR-326 was also higher in CD4 + T cells from mice with EAE during the acute phase but decreased to normal expression when disease remitted ( Fig. 2a) , similar to what occurs in patients with RRMS. To investigate whether manipulation of miR-326 can influence the development of EAE, we constructed lentiviral vectors for in vivo miR-326 manipulation. We designed vectors encoding pre-miR-326 (LV-326), a mutant miR-326 control (LV-ctrl) or its specific inhibitor (LV-sponge) and confirmed overexpression or active inhibition of miR-326, respectively (Supplementary Fig. 4 and Supplementary Methods). The term 'sponge' refers to a miR-326-specific decoy target known to suppress endogenous miR-326 activity without affecting its transcript amounts 26 . We delivered approximately 2 × 10 7 transforming units of recombinant lentivirus to mice by injection through the tail vein and assessed the in vivo efficacy of lentivirus infection 7 d later by quantitative PCR analysis of miR-326 expression in various organs (including those of the immune system) of LV-326-infected mice and LV-ctrl-infected mice. Consistent with published reports 27 , systemic administration of lentivirus led to differences in expression of the transgene among various organs, with the liver being most susceptible and the brain or lungs being least accessible to the virus (Fig. 2b) . In organs related to the immune system, infection with LV-326 led to twofold greater expression of mature miR-326 in spleen and 1.6-fold greater expression in the peripheral lymph nodes (subiliac, proper axillary and accessory axillary), but we detected little miR-326 overexpression in bone marrow or thymus (Fig. 2c) . Notably, the peripheral T lymphocyte and B lymphocyte population and CD4 + T cell/CD8 + T cell ratio in the resting state showed no difference among mice infected with those lentiviruses (Supplementary Fig. 5 ), nor did we find substantial differences between naive (CD62L + CD44 lo CD4 + ) T cells and antigen-experienced (CD62L − CD44 hi CD4 + ) T cells (data not shown), which indicates that miR-326 might not affect the homeostasis of the T lymphocyte and B lymphocyte repertoire in naive mice. After immunization of lentivirus-infected mice with an encephalitogenic peptide of myelin oligodendrocyte glycoprotein consisting of amino acids 35-55 (MOG(35-55)) on day 7 after virus injection, LV-326-infected mice developed severe EAE, whereas LVsponge-infected mice had somewhat mild EAE, both relative to that of LV-ctrl-infected mice ( Fig. 2d and Table 2 ). Histological analysis of spinal cord sections also showed that LV-326-infected mice developed prominent inflammatory infiltration and demyelination, whereas LV-sponge-infected mice showed mild CNS pathology (Fig. 2e,f) . To conclusively demonstrate that miR-326 is critical in EAE development, we first sought to further verify the expression and distribution of the lentiviral transgene in the EAE mice. Because of the low multiplicity of infection (<1) limited to systemic lentiviral administration and the resultant very weak fluorescence of green fluorescent protein (GFP) for measurement, we did sensitive FISH analysis of GFP transcripts (Supplementary Methods). We found that the proportion of virus-infected cells in total cell populations of PBLs, spleens, draining lymph nodes (DLNs; pooled peripheral lymph nodes from subiliac, proper axillary and accessory axillary lymph nodes) and CNS infiltrates from virus-infected mice with EAE was 45%, 39%, 33% and 51% respectively ( Supplementary Fig. 6a-e) . Notably, the highest transduction efficiency was in the CNS infiltrates of mice with EAE, which supports the idea that lentivirus-mediated manipulation of miR-326 contributes to altered EAE pathology.
Further analysis showed that the specific transduction efficiency in CD4 + T cells, CD8 + T cells and B cells, quantified by the percentage of positive infection in each cell subset, was around 50%, 33% and 28% respectively (as averaged for PBLs, spleen, DLNs and CNS infiltrates; Supplementary Fig. 6a-d,f) , which showed the relative selectivity of lentivirus infection for CD4 + T cells. There was no obvious difference in the transduction efficiency of naive and effector CD4 + T cells (Supplementary Fig. 7a,c) . Moreover, we also confirmed these data by flow cytometry (Supplementary Figs. 7b,c and 8) . The data presented above collectively showed that EAE pathology differed greatly in mice efficiently infected by miR-326 or lentivirus encoding its inhibitor, which demonstrated that miR-326 expression and function correlated with the development of EAE.
Promotion of T H -17 differentiation by miR-326
We then sought to determine whether the difference in EAE pathology in the three groups of lentivirus-infected mice was associated with altered infiltration of the CNS with effector helper T cells (mainly T H -17 and T H 1 cells), a hallmark of CNS inflammation in EAE. More CD4 + T cells accumulated in the CNS of LV-326-infected mice, whereas fewer CD4 + T cells were present in mice infected with LV-sponge, as measured by CD4 surface staining of Incidence indicates number of mice that developed EAE relative to total mice in group; time of onset is presented in days (mean ± s.e.m.); maximum EAE score is presented as mean (± s.e.m.); far right column is the number of mice achieving an EAE score of greater than 3 relative total mice in group. *P < 0.05, versus control (Student's t-test). Data are cumulative results from four different experiments. A r t i c l e s CNS leukocyte infiltrates (Fig. 3a) . Intracellular cytokine staining showed that both the frequency and absolute number of T H -17 cells, but not of T H 1 cells, in the CD4 + population were higher in LV-326-infected mice but lower in LV-sponge-infected mice (Fig. 3b,c) . We also investigated the correlation between IL-17 production and virus infection in CNS by FISH analysis of Il17a and the sequence encoding GFP. This showed that the percentage of IL-17-producing cells in the GFP + population was higher in CNS infiltrates from LV-326-infected mice but lower in those from LV-sponge-infected mice. In contrast, the percentage of IL-17-producing cells was similar among GFP − cells in all samples examined (Supplementary Fig. 9 ). These data collectively indicate that miR-326 functions in EAE development largely by affecting the T H -17 cell population. Next we examined effector T cells primed in peripheral lymph nodes from EAE mice in which miR-326 expression had been manipulated. We found more T H -17 cells in DLNs of LV-326-infected mice and fewer in those of LV-sponge-infected mice than in those of control mice. In contrast, T H 1 cell numbers were similar in the various groups of mice (Fig. 3d,e) . Consistent with that, genes specific for the T H -17 lineage, including Il17a, Il17f, Il22, Il21 and Il23r, were significantly upregulated in LV-326-infected mice and downregulated in LV-sponge-infected mice, whereas genes related to other helper T cell subsets, such as Ifng, Il4 and Tgfb, were unchanged in LV-326-and LV-sponge-infected mice relative to their expression in LV-ctrl-infected mice (Fig. 3f ). Antigen-specific T H -17 responses in DLN cells from LV-326-or LV-sponge-infected mice were higher and lower, respectively, as shown by measurement of IL-17 in culture supernatants of DLN cells after in vitro restimulation with MOG (35-55) (Fig. 3g) . Production of the T reg cell-related cytokine TGF-β was not obviously affected by miR-326 (Fig. 3g) . In addition, IL-17 expression in CD8 + T cells as well as in γδ T cells did not differ among mice infected with LV-ctrl, LV-326 or LV-sponge (Supplementary Fig. 10 ). Collectively these data suggest that miR-326 regulates the in vivo generation of T H -17 cells during EAE.
To directly assess if miR-326 regulated the differentiation of T H -17 cells, we did an in vitro T cell-differentiation assay. By comparing miR-326 expression in all subsets of helper T cells with that in naive CD4 + T cells, we found large amounts of miR-326 (17.4-fold more than that in naive CD4 + T cells) 'preferentially' in T H -17 cells but relatively small and similar amounts in T H 1, T H 2 and inducible T reg cells (about 1.6-fold to 3.3-fold more than that in naive CD4 + T cells; Fig. 4a) . As a control for in vitro differentiation, we measured lineage-specific transcription factors and cytokines ( Supplementary  Fig. 11a,b) . CCR6 + cells from in vitro T H -17 cell cultures had approximately fivefold higher miR-326 expression than did their CCR6 − counterparts (Fig. 4b) , along with the enrichment of Il17a expression (Supplementary Fig. 11c ). Again these data indicated that miR-326 expression is associated with mouse T H -17 cells as with human T H -17 cells. We then purified naive CD4 + CD62L + helper T cells from spleens of mice infected with LV-ctrl, LV-326 or LV-sponge and primed the cells for T H -17 differentiation in vitro. We found 2.5-fold more miR-326 expression in T cells from LV-326-infected mice (Fig. 4c) . More T H -17 cells were produced by naive CD4 + T cells from LV-326-infected mice and fewer were produced by those from LV-sponge-infected mice (Fig. 4d ). The expression of T H -17-lineage marker genes (Rorc and Il17a) and IL-17 in culture supernatants were also greater with miR-326 overexpression. In contrast, these T H -17 lineage markers were downregulated in T cells from LV-sponge-treated mice after culture in the same conditions (Fig. 4e,f) . Expression of IL-10, an anti-inflammatory cytokine also induced by T H -17 cells, however, was not affected by miR-326 expression (Fig. 4e) . The broadly used microRNA inhibitor LNA-anti-miR-326 (a locked nucleic acidmodified antisense oligonucleotide directed against miR-326) produced an inhibitory effect on T H -17 differentiation similar to that of infection with LV-sponge ( Fig. 4g-i ). We also differentiated T H -17 cells in vitro with a bicistronic retrovirus encoding miR-326, an internal ribosomal entry site and GFP. Relative to infection by control retrovirus (encoding mutant miR-326), transduction of miR-326-encoding virus resulted in a substantially higher percentage of IL-17-expressing cells in the GFP + population, whereas infection with virus encoding a specific inhibitor of miR-326 resulted in a much lower percentage of IL-17-expressing GFP + cells. In contrast, these groups had a similar percentage of IL-17-producing cells among cells gated in the GFP − population (Supplementary Fig. 12) . Together these data demonstrate that miR-326 positively regulates T H -17 differentiation both in vivo and in vitro.
To determine whether the effects of miR-326 on EAE development were due to its effect on T H -17 differentiation, we infected mice with lentivirus and induced EAE. We collected splenocytes on day 14 after EAE induction and restimulated them in vitro for 96 h with MOG (35-55). We purified enriched MOG-specific CD4 + T cells and transferred them into sublethally irradiated naive C57BL/6 mice by intravenous injection. The resultant EAE scores showed that mice given MOG-specific T cells from LV-326-infected donors had more severe disease, whereas mice transferred with LV-sponge-infected donor T cells showed less-severe signs. Thus, miR-326 expression by CD4 + T cells strongly correlated with EAE development (Supplementary Fig. 13 ).
Ets-1 is a functional target of miR-326
We then applied the prediction programs TargetScan 28 and miRanda 29 to identify the potential miR-326 targets. Two reported negative regulators of T H -17 differentiation, Ets-1 (ref. 7) and Foxp3 (A002750) 6 , have putative miR-326-binding elements in their 3′ untranslated regions (UTRs). We found that miR-326 inhibited the luciferase activity of a reporter containing the wild-type Ets1 3′ UTR but not that of a reporter with a mutated 3′ UTR unable to bind miR-326 (Fig. 5a,b) . However, miR-326 did not inhibit the luciferase activity of the reporter containing the wild-type Foxp3 3′ UTR (Supplementary Fig. 14a,b) , nor did miR-326 affect the TGF-β1-driven induction of Foxp3 in naive CD4 + T cells isolated from mice infected with lentivirus expressing miR-326 or producing 'knockdown' of miR-326 (Supplementary Fig. 14c) , which indicates that miR-326 specifically targets Ets-1. Consistent with that, miR-326 suppressed the expression of Ets-1 protein encoded by a wild-type Ets1 3′ UTR in a dose-dependent way (Fig. 5c) . Manipulation of miR-326 in CD4 + T cells by LNA-anti-miR-326, LV-326 or LV-sponge regulated the amount of endogenous Ets-1 protein but did not affect Ets1 transcripts (Fig. 5d,e) , which indicates that miR-326 functions at the translational level. Moreover, there was a similar inverse correlation between the expression of miR-326 and Ets-1 in CD4 + T cells from mice with EAE and those from patients with multiple sclerosis (Fig. 5f-i) .
To directly prove that Ets-1 is a functional target of miR-326 in the pathogenesis of multiple sclerosis, we did 'rescue' experiments with an Ets-1-expressing lentivirus containing mutated sequence encoding the recognition element of miR-326 (LV-Ets-1-3′ UTR-MRE). Transduction with LV-Ets-1-3′ UTR-MRE produces Ets1 mRNA that is resistant to miR-326-mediated translational inhibition. Compared with mice infected with LV-ctrl, mice infected with LV-326 showed aggravated EAE, whereas this aggravation was completely abrogated by coinfection with LV-Ets-1-3′ UTR-MRE. Thus, restoration of Ets-1 protein reversed the effect of miR-326 (Fig. 5j,k) . Flow cytometry analysis of cytokine production by CNS-infiltrating CD4 + T cells further supported the idea that Ets-1 is the functional target of miR-326 during T H -17 differentiation and the pathogenesis of multiple sclerosis (Fig. 5l,m) .
DISCUSSION
T H -17 cells are critically involved in the pathogenesis of chronic autoimmune diseases, including multiple sclerosis 30 , and regulators of T H -17 differentiation are considered to have valuable potential for clinical applications in the diagnosis or treatment of this category of complicated immune disorders 31 . Here we have reported a microRNA (miR-326) that is critically involved in the pathogenesis of multiple sclerosis and EAE by regulating T H -17 differentiation. We have shown that miR-326 expression in CD4 + T cells correlated well with disease in patients with relapsing multiple sclerosis and, moreover, its inhibition substantially ameliorated disease severity in the EAE model. Mechanistically, we have proven that by targeting Ets-1, a known negative regulator of T H -17 cells, miR-326 promoted the generation of T H -17 cells both in vivo and in vitro, and this was reversed by the reintroducion of an Ets1 gene generated to be resistant to miR-326 suppression.
Our data suggest miR-326 is a T H -17-associated microRNA, on the basis of the following observations. First, miR-326 expression correlated well with IL-17 expression in patients with multiple sclerosis. Second, the FISH assay of miR-326 and Il-17a in CD4 + T cells from patients with multiple sclerosis and their enrichment in CCR6 + CD4 + T cells showed that the peripheral blood of patients with relapsing multiple sclerosis had more IL-17-expressing CD4 + T cells, with high expression of miR-326 in these cells. Upregulation of miR-326 was associated only with multiple sclerosis, as patients with NMO, another CNS inflammatory disorder similar to multiple sclerosis but mediated by antoantibodies, showed no miR-326 upregulation in PBLs 32 . Third, in the in vitro differentiation model, T H -17 cells had higher expression of miR-326 than did T H 1, T H 2 or inducible T reg cells. Finally, miR-326 was functionally involved in T H -17 differentiation both in vitro and in vivo. Our findings may provide a new target for manipulating the generation of T H -17 cells in related diseases. Further exploration of the function of miR-326 in other cell types, especially those of the innate immune system, will be of great importance for understanding the cell-differentiation network of the immune system.
Generally, microRNAs are believed to function in vivo by targeting multiple functionally related proteins or a key protein target 33, 34 . In the immune system, miR-181 controls T cell antigen receptor signaling strength during T cell maturation by downregulating a set of negative regulators 35 , whereas miR-150, the hematopoiesisspecific microRNA, controls embryonic development and B cell differentiation by regulating a key target, c-Myb 36, 37 . Our data suggest miR-326 regulates T H -17 cells mainly by targeting Ets-1. As a functional miR-326 target, Ets-1 therefore represents a distinct regulator of T H -17 differentiation. Although published work has shown that Ets-1 restrains T H -17 differentiation without affecting the induction of RORγt 7 , the lineage-defining transcription factor of T H -17 cells, the mechanisms regulating its own expression and the physiological relevance of Ets-1 have remained largely unclear. Our study has now shown that Ets-1 expression was substantially downregulated by miR-326 in patients with relapsing multiple sclerosis. Moreover, the greater disease severity and greater number of T H -17 cells in LV-326-infected mice was largely reversed by coinfection of these mice with lentivirus expressing Ets1 with a mutated 3′ UTR. This indicates Ets-1 indeed acts as a key target of miR-326, at least in the development of EAE and multiple sclerosis.
The immunosuppressive drugs now approved for the clinical treatment of multiple sclerosis work mainly by increasing the frequency of T reg cells or by changing the T H 1-T H 2 bias 38 . Drugs that target T H -17 cells, however, have not yet been applied to multiple sclerosis therapy. We found that miR-326 was substantially downregulated in a group of patients after glucocorticoid treatment (data not shown), the routine therapy for patients with multiple sclerosis to relieve symptoms caused during an acute relapse 39 , which indicates that miR-326 expression itself not only correlates well with disease severity and the relapsing phase of multiple sclerosis but also is under the regulation of disease-modifying drugs or environmental factors in patients with multiple sclerosis. Combined with the findings that specific and inversely correlated upor downregulation of the expression of miR-326 and Ets-1 was easily detected in blood samples from patients with multiple sclerosis, our results suggest that this microRNA-protein pair is of potential value as a biomarker for the diagnosis of multiple sclerosis disease, assessment of its prognosis or evaluation of drug responses. Also, elucidation of the specific signals that regulate miR-326 expression in disease will deepen the knowledge of how this noncoding RNA-mediated mechanism contributes to the pathogenesis of multiple sclerosis and help to identify new therapeutic approaches by targeting miR-326 for multiple sclerosis treatment. In summary, miR-326 may serve as a new and valuable target for clinical applications in patients with multiple sclerosis.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureimmunology/. Accession codes. UCSD-Nature Signaling Gateway (http://www. signaling-gateway.org): A000889 and A002750.
